On Monday, Tilray Brands, Inc. announced a significant milestone for its cannabis cultivation facility, Aphria RX GmbH, located in Germany. The facility obtained a cultivation license under Germany’s recent adult-use cannabis legalization law.
Initially, Aphria RX received a license in 2019 to grow cannabis for Germany’s medical cannabis program. However, with this latest license, the company now has the authorization to cultivate and manufacture a wider range of products. Notably, the cultivator is diversifying its genetics portfolio from the three strains previously approved for the medical cannabis program to a total of 31 strains sanctioned under the Cannabis Act.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray, expressed excitement about the new license. She emphasized how it would enhance access to top-tier medical cannabis in Germany and enable the expansion of treatment options available to patients. In a press release, she acknowledged the German Government’s confidence in Tilray and commended the team for their pioneering efforts in medical cannabis cultivation and patient care.
The adult-use cannabis legalization law in Germany became effective on April 1, ushering in a substantial shift in cannabis regulations. Notably, the law removed cannabis from Germany’s Narcotics List, allowing individuals aged 18 and above to legally possess and consume cannabis. While the initial proposal included plans for a regulated adult-use sales framework, lawmakers opted for a more cautious approach, stepping back from establishing a fully regulated marketplace.
Presently, access to cannabis primarily relies on homegrown sources, with recent developments such as the introduction of new cannabis clubs. These clubs, launched this month, cater to a limited membership base, offering a legal avenue for members to procure cannabis within the bounds of the law.
Related on Weedly: Keep exploring the Weedly Glossary, our strain reviews, the Learn hub, our Canada coverage and our USA coverage.
Sources & further reading: For authoritative background see the CDC, peer-reviewed studies on PubMed, Project CBD, Health Canada and NIDA (US National Institute on Drug Abuse).
The context: Germany’s medical cannabis market
Tilray’s approval to cultivate cannabis in Germany is significant because Germany has become one of Europe’s most important medical cannabis markets. Even before its 2024 recreational legalization, Germany permitted medical cannabis and relied heavily on imports to supply patients. Domestic cultivation approvals like Tilray’s help build local supply, reducing dependence on imported product and strengthening Germany’s position in the European medical cannabis industry. Understanding the scale and importance of Germany’s medical market is key to appreciating why a major producer securing cultivation rights there is a notable development for the industry.
Who Tilray is
Tilray is one of the world’s largest and best-known cannabis companies, with international operations spanning cultivation, production and distribution across multiple countries. As a major global player, its activities are closely watched as indicators of industry trends. Securing cultivation approval in Germany reflects both the company’s international expansion strategy and the attractiveness of the German market. For a company of Tilray’s scale, a foothold in Germany — Europe’s largest economy and a growing cannabis market — represents a strategically important position in one of the industry’s most promising regions.
Why domestic cultivation matters
Domestic cultivation approvals matter because they reshape supply chains. Historically, Germany imported much of its medical cannabis from countries like Canada and the Netherlands. Building domestic cultivation capacity — as Tilray’s approval enables — allows for more locally produced, potentially more reliable and cost-effective supply, and strengthens Germany’s self-sufficiency in medical cannabis. As the German market grows, especially following recreational legalization, domestic production becomes increasingly valuable. Cultivation approvals for major producers thus signal the maturation of Germany’s cannabis industry from an import-dependent market toward one with significant home-grown supply.
The competitive landscape
Germany’s growing cannabis market has attracted intense interest from major international companies competing for position. Securing cultivation rights, distribution networks and market share in Germany is a strategic priority for global cannabis firms, given the country’s size and growth potential. Tilray’s approval is part of this broader competitive scramble, as companies vie to establish themselves in what many see as Europe’s most important cannabis market. This competition drives investment and industry development, benefiting the market’s maturation, even as it means major players jockeying for advantage in a high-stakes environment.
The impact of recreational legalization
Germany’s 2024 recreational legalization further raised the stakes for cannabis cultivation and supply in the country. While recreational supply flows through nonprofit clubs and home growing rather than commercial sales, the overall expansion of Germany’s cannabis framework increases the importance of domestic production capacity and industry infrastructure. Companies positioned in the German market, like Tilray, stand to benefit from the country’s evolving and expanding cannabis landscape. Cultivation approvals gain added significance in this context, as Germany becomes an even more central player in European cannabis.
What it means for patients and the industry
For German patients, expanded domestic cultivation can mean more reliable supply of medical cannabis, potentially improving availability. For the industry, approvals like Tilray’s signal Germany’s growing importance and the shift toward local production. This benefits the broader European cannabis sector by strengthening supply chains and demonstrating the commercial viability of the German market. As Germany’s cannabis framework matures, domestic cultivation by major producers helps ensure the market can meet demand, supporting both patient access and industry growth in one of the world’s most watched cannabis markets.
Learn more
For a full explanation of Germany’s cannabis rules and market — including possession limits, the club system and the medical framework — see our guide to whether cannabis is legal in Germany. For the broader industry picture, see the global cannabis market. Explore more on our International desk and learn key terms in the cannabis glossary.
The bottom line
Tilray’s approval to cultivate cannabis in Germany reflects the growing importance of the German market and the industry’s shift toward domestic production. As one of Europe’s largest medical cannabis markets — further expanded by 2024 recreational legalization — Germany has attracted intense competition among major global producers. Domestic cultivation strengthens supply chains, benefits patients and signals the maturation of Germany’s cannabis industry. Tilray’s foothold there is a strategically significant development in one of the world’s most watched cannabis markets. As always, verify current rules before acting. This article is informational; verify local legality before acting on it.
